Today’s company is helping the medical industry fight COVID-19…
According to the New York Times, the seven-day average of daily COVID-19 deaths in the U.S. surpassed 2,000 last weekend. That’s a high we haven’t seen since March. And as the Delta variant continues to drive up cases around the world, it’s clear the pandemic is far from over. So today, we’re checking in on a major player in COVID-19 vaccine development…
Repligen (RGEN) is a $20 billion leader in life sciences. When we last highlighted the company, it was helping to purify COVID-19 vaccines. Since then, Repligen has launched its own affinity resin to be used in the purification process… And it’s continuing to put its innovations to good use in this difficult time. COVID-19-related sales made up 27% of Repligen’s revenue in the most recent quarter, while total revenues – including its base business – grew 69% year over year to $163 million.
As you can see, RGEN is up more than 120% over the past year. It also recently hit a fresh all-time high. And as Repligen continues to aid in the fight against COVID-19, we can expect this uptrend to continue…
The next three months could be very challenging and critically important for anyone with money in the markets. You need a big-picture plan... and you need to take specific actions starting TODAY. Don't get stuck in the "denial" trap so many fall into. 50-year Wall Street veteran Marc Chaikin recently published his full big-picture plan, which lays out – based on more than 100 years of data – exactly what you can expect in the markets this year (and in 2026, too). Click here for Marc's critical new update.
Source: Daily Wealth’s Market Notes
